In a double-blind, randomized trial, 102 healthy elderly subjects were inoculated with one of four preparations: (i) intranasal bivalent live attenuated influenza vaccine containing cold-adapted A/Kawasaki/86 (HlN1) and cold-adapted A/Bethesda/85 (H3N2) viruses; (ii) parenteral trivalent inactivated subvirion vaccine containing A/Taiwan/86 (HlN1), A/Leningrad/86 (H3N2), and B/Ann Arbor/86 antigens; (iii) both vaccines; or (iv) placebo. To determine whether local or systemic immunization augmented mucosal immunologic memory, all volunteers were challenged intranasally 12 weeks later with the inactivated virus vaccine. We used a hemagglutination inhibition assay to measure antibodies in sera and a kinetic enzyme-linked immunosorbent assay to measure immunoglobulin G (IgG) and IgA antibodies in sera and nasal washes, respectively. In comparison with the live virus vaccine, the inactivated virus vaccine elicited higher and more frequent rises of serum antibodies, while nasal wash antibody responses were similar. The vaccine combination induced serum and local antibodies slightly more often than the inactivated vaccine alone did. Coadministration of live influenza A virus vaccine did not alter the serum antibody response to the influenza B virus component of the inactivated vaccine. The anamnestic nasal antibody response elicited by intranasal inactivated virus challenge did not differ in the live, inactivated, or combined vaccine groups from that observed in the placebo group not previously immunized. These results suggest that in elderly persons cold-adapted influenza A virus vaccines offer little advantage over inactivated virus vaccines in terms of inducing serum or secretory antibody or local immunological memory. Studies are needed to determine whether both vaccines in combination are more efficacious than inactivated vaccine alone in people in this age group.
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Influenza epidemics are a significant cause of severe illness and mortality in elderly people, even among those without chronic medical problems (4) . Persons aged 65 years or older have therefore been targeted along with individuals in other high-risk groups to receive influenza vaccinations annually (22) . Rates of protection against influenza illness afforded by commercially available inactivated virus vaccines have generally been lower in elderly individuals, particularly those who are institutionalized, than efficacy rates reported in studies of younger populations (3, 5, 14, 15, 18, 21, 30, 35) . These observations, which suggest that the immune response to inactivated influenza vaccines may decline with advancing age, have prompted the search for alternative approaches to vaccination that will more effectively stimulate immunity to influenza in elderly individuals.
Immunologic factors, in addition to serum antibody, including the presence of local (secretory) immunoglobulin A (IgA) antibody in the upper respiratory tract, have been shown to correlate with resistance to influenza virus infection in children and young adults (10, 23) . Optimal protection may therefore require both systemic and local components of the humoral immune response. Parenterally administered inactivated virus vaccines induce antibody in the serum, but they are less effective at stimulating the production of * Corresponding author.
secretory IgA antibody (9, 11) . On the other hand, intranasally administered, live attenuated cold-adapted (ca) influenza A reassortant virus vaccines effectively elicit both serum and secretory antibody responses in children and young adults (11, 27) . In a previous study involving healthy elderly subjects (32) , we reported that a monovalent live attenuated ca influenza A HlNl virus vaccine induced infrequent and short-lived systemic and local antibody responses when administered alone, and it only marginally augmented the secretory antibody response to parenteral inactivated virus vaccine when the two vaccines were given in combination. Vaccines containing hemagglutinin and neuraminidase components from both HlNl and H3N2 subtypes are likely to be more efficacious than monovalent preparations during influenza A epidemics. The present study was therefore undertaken in persons aged 60 years or older (referred to as elderly) to reexamine our previous findings with a bivalent live attenuated ca influenZa A vaccine comprising HlNl and H3N2 viruses.
In our earlier study, titers of local IgA antibody elicited by live, inactivated, or both influenza virus vaccines declined rapidly in elderly subjects and returned to near base-line levels by 3 months after vaccination (32) . It is possible, however, that those volunteers immunized with live virus sequent exposure to related antigens. This question was previously addressed in a study with children who were infected with attenuated influenza A virus vaccine but whose nasal antibody levels had returned to barely detectable levels 1 year later (38) . These children were able to mount an anamnestic influenza virus-specific secretory IgA antibody response following intranasal administration of inactivated influenza virus vaccine. As part of the present investigation, we conducted a similar study by rechallenging the elderly subjects intranasally with inactivated virus vaccine 12 weeks after the initial immunization and then examining the local and systemic immune responses. 29, 1991 on November 6, 2017 by guest http://jcm.asm.org/ Downloaded from time. The serum IgG KELISA rate ratios in placebo recipients were normally distributed, and 95% upper confidence limits were readily calculated. When determined in this manner, significant serum antibody responses were defined as post-KELISA/pre-KELISA rate ratios that were .1.34 for A/Kawasaki (HlNl), .1.46 for A/Bethesda (H3N2), and .1.37 for B/Ann Arbor. These ratios were used to compare serum IgG KELISA rates for each individual, first, between prevaccination and 4-or 12-week postvaccination specimens and, second, between the 12-week postvaccination (prechallenge) specimen and the highest of the three postchallenge specimens.
MATERIALS AND METHODS
Because of the wide variability in concentrations between different nasal wash specimens, the nasal wash IgA KELISA rates were normalized to a total protein concentration of 350 ,ug/ml prior to further analysis by using the following formula: KELISA ratecorTected = KELISA ratesample x [(350 ,ug/ml)/(protein concentrationsample)]. This total protein concentration of 350 ,ug/ml approximated the median among all specimens tested, as determined by a colorimetric assay (Pierce, Rockford, Ill.). Unlike the serum IgG data, the ratios between prevaccination, 4-week postvaccination, and 12-week postvaccination nasal wash IgA KELISA rates in placebo recipients were not normally distributed and contained multiple outlier values such that useful 95% upper confidence limits were not obtained. Cutoff ratios for defining significant rises in nasal wash antibodies were therefore arbitrarily determined as the minimum values associated with response rates of <10% among placebo recipients. This choice of values corresponded to post-KELISA/pre-KELISA rate ratios that were .1.40 for A/Kawasaki (HlNl) or .2.00 for A/Bethesda (H3N2). These cutoff ratios were used to compare nasal wash IgA KELISA rates for each individual, first, between prevaccination and 4-week postvaccination specimens and, second, between the 12-week postvaccination (prechallenge) specimen and the highest of the three postchallenge specimens.
Statistical analysis. Differences between various subject groups were analyzed by using several methods: (i) the Fisher exact test to compare proportions of antibody responses, (ii) the two-tailed unpaired Student t test to compare mean prevaccination antibody levels or mean increases in serum antibody levels, and (iii) the two-sample Wilcoxon (Mann-Whitney U) test to detect significant shifts in the distributions of post-KELISA/pre-KELISA rate ratios of nasal wash IgA antibody. The modified Bonferroni inequality was applied when appropriate to account for multiple possible comparisons (20) . Differences within vaccine groups were analyzed two ways. We used the Fisher exact test to compare proportions of responders with low versus high prevaccination antibody titers, and the two-tailed paired Student t test to compare mean antibody levels from serially collected specimens within a group.
RESULTS
Study population. Volunteers aged 60 to 90 years (71 ± 6 years, mean ± standard deviation) were inoculated with live ca virus vaccine alone (n = 24), inactivated virus vaccine alone (n = 26), both vaccines (n = 26), or placebo (n = 26). Of the subjects in each group, approximately one-half had a prevaccination HAI antibody titer of <1:16 to A/Kawasaki (HlNl), and approximately one-third were immunized with inactivated influenza vaccine previously. There were no significant differences among the four vaccine groups in their mean age, gender, or prevaccination levels of serum HAI, serum KELISA IgG, or nasal wash KELISA IgA antibodies to any of the test antigens, with one exception. There was a higher mean serum IgG A/Bethesda (H3N2) KELISA rate in recipients of the vaccine combination than in recipients of the inactivated vaccine alone (55.8 ± 24.3 versus 34.2 ± 18.0; P < 0.005) ( Table 1) .
Safety. The live and inactivated virus vaccines were well-tolerated. None of the volunteers immunized with live ca viruses alone reported illness during the 4-day postvaccination period. Three inactivated vaccine recipients had a local reaction at the injection site. Among the subjects who received both vaccines, three had fever (37.9°C) (two with rhinitis), and two had local reactions.
Serum antibody responses after the initial vaccination. Antibody responses after the initial vaccination are summarized in Table 1 . Only a few of the live ca virus vaccinees developed fourfold increases in serum HAI antibody or significant elevations of KELISA IgG antibody to either HlNl or H3N2 virus antigen. In contrast, serum antibody responses were achieved by substantial numbers of subjects immunized with inactivated virus vaccine alone or with the vaccine combination. A greater proportion of recipients of either inactivated or combined vaccines mounted serum responses of HAI or KELISA IgG antibody to HlNl antigen or of KELISA IgG antibody to H3N2 antigen than did those who were given live ca viruses along (P < 0.05 in all cases but one). The exception was the HlNl KELISA IgG response in the live versus inactivated virus vaccine groups. Serum HAI response rates to H3N2 antigen were relatively low and did not differ significantly between the vaccine groups. Figure 1 depicts the time course of serum antibody responses. As expected, during the 12 weeks after inoculation of the placebo group, mean HAI titers and KELISA rates remained essentially unchanged from prevaccination levels. Mean serum antibody levels rose marginally, if at all, following immunization with the live ca viruses alone, and none of these changes were significant relative to those found in the placebo group. In contrast, 4 weeks after immunization, both the inactivated vaccine alone and the vaccine combination elicited substantial rises in mean serum levels of all antibodies, and the magnitudes of these increases were comparable between the two groups in all cases. Compared with the responses elicited by the live ca vaccine alone, mean increases in serum levels of both HAI and KELISA IgG antibodies to HlNl and H3N2 viruses were significantly greater after immunization with inactivated vaccine alone (P < 0.05 in all cases) or the vaccine combination (P < 0.01 in all cases). Twelve weeks after the initial vaccination, mean serum antibody levels in both inactivated and combined vaccine recipients had declined modestly from the peak levels achieved 4 weeks postvaccination.
There were no significant differences in the frequencies or magnitudes of serum HAI and KELISA IgG influenza B antibody responses in persons immunized with inactivated vaccine compared with those in recipients of both vaccines (Table 2 ). This similarity suggested that the serum antibody response to the influenza B component of the inactivated virus preparation is not altered by the simultaneous administration of ca type A viruses.
Effect of prevaccination serum antibody levels on seroresponse to initial vaccination. Among subjects immunized with live ca viruses alone, HAI seroresponses were infrequent. Only two of these individuals (with prevaccination HAI titers of 1:4 and 1:512, respectively) had a fourfold or greater rise of HAI antibody to A/Kawasaki (HlNl), and no indi- Compared with live virus vaccinees, a higher proportion of recipients of the vaccine combination mounted any antibody response to HlNl (P < 0.01) and H3N2 (P = 0.053) viruses. Inactivated vaccine alone also elicited higher rates of overall antibody response than did live ca viruses, but these differences were not statistically significant.
Serum and nasal wash antibody responses following intranasal inactivated virus challenge. It is most likely that all the elderly subjects, even those with low levels of serum HAI antibody, were previously infected with influenza A HlNl and H3N2 viruses, and were thus immunologically primed for secondary responses to related strains. To distinguish between anamnestic responses induced by previous infection and those induced by vaccination, we compared the postchallenge antibody responses of placebo recipients (who served as immunologic controls) with those of vaccinees. Whereas fourfold or greater rises of serum HAI antibody were rarely elicited by the 12-week challenge, significant increases of serum HlNl and H3N2 IgG antibody were detected by the more sensitive KELISA in approximately 20 to 30% of placebo recipients (Table 3) . Similarly, the placebo group was found to have little, if any, change in mean serum HAI antibody titers but a statistically significant peak rise in mean KELISA rates for both HlNl (P < 0.05, paired Student t test) and H3N2 (P < 0.05, paired Student t test) serum IgG antibody (Fig. 1) . In the groups immunized with live ca viruses alone or the vaccine combination, the frequency and magnitude of serum antibody responses to the intranasal inactivated virus challenge were generally less than, although not statistically different from, those observed in the placebo group. Persons who were initially immunized with inactivated virus vaccine alone, however, [20] ).
responses between the recipients of any vaccine regimen and recipients of placebo.
DISCUSSION
The present study with a bivalent ca reassortant influenza A virus vaccine confirms our previous finding with a monovalent preparation that live attenuated viruses, although well-tolerated, are poorly immunogenic in a population of healthy elderly individuals. Prior influenza infections in elderly persons may result in an inverse correlation between serum antibody levels before vaccination and seroconversion rates after vaccination (19, 25, 31) . To control for preexisting antibody, we stratified our subjects on the basis of screening titers of HAI antibody to the HlNl vaccine component prior to randomization into vaccine groups. The low to moderate frequencies of HAI antibody response among our elderly subjects were similar to those reported previously for noninstitutionalized older persons after vaccination with inactivated or live influenza virus vaccines (1, 2, 7, 8, 16, 24, 25) . The present results also corroborate earlier observations by us and others (16, 32) that older adults mount greater seroresponses to inactivated influenza virus vaccines than they do to live attenuated viruses. In this study, the KELISA was more sensitive than HAI in detecting antibody responses in serum. Better detection was expected since the minimum fold rise in antibody levels that defined a significant response was smaller for KELISA than it was for the HAI antibody. Since KELISA with whole virus antigen presumably detects antibodies to external glycoproteins as well as to other more conserved viral proteins, this assay may not be expected to discriminate well between heterologous responses. It was therefore noteworthy that the patterns of antibody production detected by HAI and KELISA were quite similar in the present study. Seroresponses to both HlNl and H3N2 viruses were meager in recipients of live ca viruses alone. In contrast, recipients of inactivated vaccine alone or the vaccine combination demonstrated significant serum antibody responses relative to those in the live virus group, but neither regimen was superior to the other.
In a previous study with healthy elderly subjects (32), we reported that the frequency of a fourfold or greater rise in HA-specific nasal wash IgA was not different between recipients of monovalent ca A/Kawasaki (HlNl) or inactivated A/Taiwan (HlNl). Because of unexplained rises of nasal wash IgA KELISA rates in three placebo recipients in the present study, satisfactory cutoff rate ratios for defining a significant response could not be derived in the same manner as they were for serum antibodies. We therefore used two alternative methods to analyze the nasal wash data and found that both approaches yielded similar results (viz., comparable responses between live and inactivated vaccine groups). Despite the technical difficulties encountered, KELISA appears to be much more sensitive than the traditional HAI or endpoint titration ELISA for detecting antibody responses. The present data confirm our previous findings, and they extend our observations to a live attenuated bivalent vaccine containing a ca influenza A H3N2 virus component. Among older adults with chronic diseases, Gorse and colleagues (17) compared local hemagglutininspecific IgA antibody response rates following immunization with ca A/California (HlNl) or ca A/Washington (H3N2) virus to those elicited 1 year later in the same persons by inactivated virus vaccine. They found no significant difference between the live and inactivated virus vaccines in the Hi response, but they did observe a more frequent H3 response in the live ca virus recipients (17) . The results presented here (i.e., the relative abilities of live attenuated and inactivated virus vaccines to stimulate a local antibody response in older adults) may differ from those of Gorse et al. (17) because of inherent differences in immunogenicity between ca viruses derived from different wild-type parent strains. Likewise, the different ages or background immunity to influenza of study populations could account for the contrasting results. Geometric mean titers of prevaccination serum HAI antibody to both HlNl and H3N2 vaccine viruses were approximately two to three times higher among our healthy elderly subjects compared with those among the older adults in the other study (17) . It has been shown previously (12, 13) (6, 9, 11, 23, 27, 33, 39) .
We previously reported that nasal wash IgA antibody responses in elderly volunteers are more frequent and of greater magnitude after the simultaneous administration of live attenuated and inactivated influenza virus vaccines than they are after administration of inactivated vaccine alone (32 (7, 31) . The mechanism that accounts for this observation is unclear.
The present results, considered together with those of our earlier investigation, fail to demonstrate any major advantage of live attenuated ca influenza A viruses as an alternative to commercially available inactivated virus vaccines in healthy elderly subjects. It remains possible that those elderly persons who are infected with live ca virus represent a subset that is at increased risk of serious illness following wild-type virus infection. If so, live attenuated virus vaccines may be efficacious in a population of elderly subjects. A recent report suggested that ca virus vaccines may be efficacious in seropositive adults, although it should be noted that vaccine-induced protection was associated with a significant local antibody response in the majority of subjects (36) . The results presented here also suggest that live virus vaccine does not adversely affect the immunogenicity of inactivated virus vaccine when both are administered in combination. Future studies need to explore the potential benefit of using live attenuated viruses as a coimmunogen with inactivated virus vaccine, particularly during influenza epidemics when there is a major antigenic difference between the vaccine component and the circulating wild-type strain. Based on the immunogenicity data from our studies, ca influenza viruses do not appear to be a suitable alternative to inactivated virus vaccines for immunization of people in this age group. Greater attention should be directed to the development of better adjuvants or immunomodulators to improve the immunogenicity and efficacy of live and inactivated influenza virus vaccines for populations of elderly subjects.
